Share this to:

Support & Insight for the Autumn of Life

Judge Ends Shortage of Namenda-IR for Alzheimer’s

Regular Namenda for Alzheimer’s has been in short supply. A federal judge has stepped in to fix that.
Find out how.

Regular Namenda® for Alzheimer’s has been in short supply lately. Fortunately, a federal judge has stepped in to fix that.

U.S. District Judge Robert Sweet ordered that the drug Namenda-IR be made available for 30 days after generic alternatives start hitting pharmacy shelves on July 11 “in order to allow for an orderly transition.”

Namenda-IR (generic memantine) is made by Actavis PLC. Actavis has been trying to encourage people using regular Namenda-IR to replace it with the new extended-release Namenda-XR. They have been using a questionable marketing technique called a "Forced Switch".

Now, the judge’s injunction orders the company to inform doctors and pharmacists of what will be happening in the months ahead. It also requires Actavis not to impose any hurdles for filling prescriptions of regular Namenda-IR.

Actavis said it will appeal Judge Sweet’s ruling. The company said that Namenda-XR® is an extended release pill. Therefore, a person can take it once daily instead of the usual twice. Actavis claims this is better for both patients and caregivers and that demand is growing.

The flipside is that brand-name medications are almost always a lot more expensive.

The ruling will have “no impact on its ability to continue focusing its resources on transitioning patients” to the new drug.

Eric Schneiderman, who is New York’s Attorney General, gets the credit for initiating the proceedings that led to this court order. He alleged that the shortages of regular Namenda IR violated anti-trust and state laws, because Actavis was trying to prevent competition from memantine. Memantine is the cheap generic version of Namenda-IR that is coming out in July.

Schneiderman said, “Unfortunately, schemes to block competition, without considering the consequences to patients, are a growing trend in the health care industry.” Fortunately for people with Alzheimer’s, Namenda’s road has been smoothed out.

To learn more, see the videos and articles:

Notify of

Inline Feedbacks
View all comments
B. Berger

B. Berger

Visit Our Pages On:


This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chaffe, the important articles & videos from each week’s river of news. With a new post on Alzheimer’s or dementia appearing on the internet every 7 minutes, the site’s focus on the best information has been a help to many over the past 15 years. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor


Common Alzheimer's Medications Slow Cognitive Decline
Swedish researchers find that cholinesterase inhibitors provide cognitive benefits and reduce mortality for up to fiv...
Lilly's Donanemab: The 3rd New Alzheimer's Drug
Now, a third new Alzheimer's drug expected to be approved by the Food and Drug Administration (FDA),. The field of ne...
Leqembi Medication for Alzheimer's (Generic: Lecanemab)
Alzheimer's Drug Leqembi Gets Full FDA and MEDICARE Approval
First drug to modestly slow Alzheimer's cognitive decline, based on 1,800 patients.
Would love your thoughts, please comment.x
News, Treatments, Care Tips

Subscribe To The Weekly Newsletter

videos & articles on Research & Prevention
News to Get at the Truth

Subscribe To Our Weekly Newsletter